In Vivo Imaging Facility

体内成像设备

基本信息

批准号：
10254105
负责人：
Jessie Nedrow
金额：
$ 22.39万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-09-10 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10254105
关键词：
Address Aftercare Algorithms Animal Cancer Model Antigen Receptors Antineoplastic Agents Apoptosis Back Biological Markers Budgets Cancer Center Cancer Center Support Grant Cancer Model Cell Communication Cell physiology Cells Clinical Clinical Research Clinical Trials Clinical assessments Communication Contrast Media Detection Development Diagnosis Disease Drug Monitoring Early treatment Evaluation Event FDA approved Funding Genomics Goals Head and Neck Squamous Cell Carcinoma Human Image Imaging Techniques Imaging technology Immune Immune response Immunity Immunotherapy Journals Magnetic Resonance Imaging Malignant Neoplasms Measurement Measures Medical Imaging Methodology Methods Modality Monitor Names Nature Neoplasm Metastasis Nuclear Optics Peer Review Pharmacotherapy Positron-Emission Tomography Production Prognosis Protocols documentation Publications Radiogenomics Radiology Specialty Radionuclide therapy Research Personnel Resource Sharing Rodent Model Scanning Services Solid Neoplasm Staging Testing Tracer Treatment Efficacy Tumor Markers Tumor Volume Tumor-infiltrating immune cells Validation bench to bedside bioluminescence imaging cancer cell cancer imaging cancer research center director cancer therapy clinical imaging co-clinical trial early detection biomarkers fluorodeoxyglucose fluorodeoxyglucose positron emission tomography glucose metabolism high dimensionality human model imaging biomarker imaging facilities in vivo in vivo imaging in vivo imaging system melanoma member molecular imaging molecular marker multimodality non-invasive imaging novel novel therapeutics pre-clinical pre-clinical assessment preclinical imaging programs quantitative imaging radiomics radiotracer receptor recruit repository response targeted agent theranostics treatment response tumor tumor growth tumor microenvironment tumorigenesis

项目摘要

Abstract: In Vivo Imaging Facility (IVIF) Advances in cancer management require the development of new therapies, and state-of-the-art imaging technologies are needed to assess response to those therapies. The Hillman Cancer Center (HCC) In Vivo Imaging Facility (IVIF) provides novel quantitative imaging techniques that trace biomarkers of molecular events and immunotherapy response associated with effective cancer therapy. Validation of advanced imaging techniques that are specific for relevant cellular processes are required to detect and measure the efficacy of novel anticancer therapies and measure early tumoricidal response. As part of this facility, PET tracers targeting various tumor markers and immune cells in the tumor microenvironment, as well as complementary optical and MR methodologies, are being developed to sensitively and specifically quantify drug-cancer cell interactions. The IVIF provides a critical shared resource for testing PET tracers in in vivo rodent models of cancer and validating promising agents in humans through quantitative imaging trials. The overall goal of the IVIF is to provide pre-clinical and clinical imaging services to HCC investigators to assist in visualizing mechanisms of biomarker action, provide approaches for early disease detection, and monitor therapeutic efficacy. The IVIF supports all 7 programs at HCC, and has contributed to high impact publications in Immunity, Cancer Cell, Theranostics and Nature Communications, among other journals. IVIF had 76 users of which 66 were HCC investigators. Of the 66 HCC users, 42 had peer-reviewed funding. The Specific Aims of the IVIF: (1) Assess biomarker expression throughout cancer treatment using a single modality or a combination of modalities, both clinically and pre-clinically; (2) provide non-invasive imaging services for monitoring therapeutic efficacy in humans and animal models of cancer; (3) provide standard imaging assessment services to evaluate all types of treatment response using the FDA-approved and other standard imaging assessment criteria; (4) provide and incorporate novel imaging analytics such as radiomics and radiogenomics for clinical and preclinical tumor characterizations; and (5) develop novel imaging algorithms, advanced imaging analytics, radiotracers, and contrast agents for clinical and pre-clinical oncological imaging to monitor and evaluate treatment response and agents for targeted radionuclide therapy. Key Services Include: (1) PET radiotracer development and production for human PET-CT and PET-MRI; (2) pre-clinical PET-CT and clinical or preclinical assessment of biomarker expression during cancer treatment; and (3) developing methods for monitoring drug treatments and other types of therapy with PET-CT, CT, and/or MRI through the use of molecular imaging, standard imaging assessments, tumor volumetrics, radiomics and radiogenomics.

摘要：体内成像设备（IVIF）癌症治疗的进步需要开发新疗法和最先进的成像技术需要技术来评估对这些疗法的反应。希尔曼体内癌症中心 (HCC) 成像设施 (IVIF) 提供新颖的定量成像技术，可追踪分子生物标志物与有效癌症治疗相关的事件和免疫治疗反应。先进成像的验证需要针对相关细胞过程的技术来检测和测量其功效新的抗癌疗法并测量早期杀肿瘤反应。作为该设施的一部分，PET 示踪剂针对肿瘤微环境中的各种肿瘤标志物和免疫细胞，以及互补正在开发光学和 MR 方法，以灵敏且特异性地量化药物-癌细胞互动。 IVIF 为在啮齿动物体内模型中测试 PET 示踪剂提供了重要的共享资源癌症并通过定量成像试验验证人类有前途的药物。该项目的总体目标是 IVIF 将为 HCC 研究人员提供临床前和临床影像服务，以协助可视化生物标志物作用机制，提供早期疾病检测和监测治疗的方法功效。 IVIF 支持 HCC 的所有 7 个项目，并为以下领域的高影响力出版物做出了贡献《免疫》、《癌细胞》、《治疗诊断学》和《自然通讯》等期刊。 IVIF 有 76 位用户其中 66 名是 HCC 调查员。在 66 名 HCC 用户中，42 名获得了同行评审的资助。 IVIF 的具体目标：(1) 使用单一方法评估整个癌症治疗过程中生物标志物的表达临床和临床前的模式或模式组合； (2)提供非侵入性成像监测人类和动物癌症模型治疗效果的服务； (3)提供标准影像评估服务，使用 FDA 批准的和其他方法评估所有类型的治疗反应标准影像评估标准； (4) 提供并整合新颖的成像分析，例如放射组学用于临床和临床前肿瘤特征的放射基因组学； (5) 开发新颖的成像技术用于临床和临床前的算法、高级成像分析、放射性示踪剂和造影剂肿瘤成像用于监测和评估治疗反应以及靶向放射性核素治疗的药物。主要服务包括：（1）用于人体PET-CT和PET-MRI的PET放射性示踪剂开发和生产； (2) 临床前 PET-CT 以及癌症治疗期间生物标志物表达的临床或临床前评估； (3) 开发使用 PET-CT、CT、和/或 MRI 通过使用分子成像、标准成像评估、肿瘤体积测量、放射组学和放射基因组学。